This page is the primary source of information for your migration steps and resources. Always start with this page to contact us with questions, find dates and take action on confirming your status.

Following the formal safety review of Cohort 1, no safety or tolerability issues were observed, allowing the company to move forward with Cohort 2. The company plans on releasing more detailed results ...

GT Biopharma, Inc. announced the successful completion of Cohort 1 in its Phase 1 trial for GTB-3650, a treatment for relapsed or refractory CD33 expressing hematologic malignancies. Following a ...

-- Patients in Cohort 1 have progressed to the open label, Phase 2 portion of ELEVATE-44-201 -- -- Company on track to report ELEVATE-44-201 Cohort 1 data in Q2 2026, with Cohort 2 data by end of year ...

Each startup receives $300,000, increasing the total investment due to the larger group. Selected studios gain mentorship and hands-on support from global industry leaders. Applications for Cohort 3 ...

Lorlatinib Versus Crizotinib in Patients With Advanced ALK-Positive Non–Small Cell Lung Cancer: 5-Year Outcomes From the Phase III CROWN Study Cohort 2 included 38 patients (61% male; median age 72.5 ...

BOSTON, Feb. 17, 2026 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (Nasdaq: TRDA) today announced that an independent Data Monitoring Committee (DMC), per study protocol, has reviewed all available ...

-- Company on track to report ELEVATE-44-201 Cohort 1 data in Q2 2026, with Cohort 2 data by end of year -- BOSTON, Feb. 17, 2026 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (Nasdaq: TRDA) today ...